10-Q: Perrigo Reports Q2 Loss Amid Restructuring and Impairments

Perrigo Company plc's Q2 2026 Form 10-Q reveals a net loss driven by significant goodwill impairments and restructuring charges, though a gain from a business divestiture provided some offset.

Summary

• Perrigo Company plc reported a net loss of $324.1 million for the six months ended June 27, 2026, compared to a net loss of $14.8 million in the prior year period.
• Net sales for the six months decreased by 5.2% to $1,992.0 million from $2,100.2 million in the prior year.
• The company recorded a significant goodwill impairment charge of $331.8 million during the six months ended June 27, 2026.
• A pre-tax gain of $129.5 million was recognized from the sale of the Dermacosmetics Business, completed on April 30, 2026.
• Operating expenses increased significantly due to the goodwill impairment charge, impacting operating income which was a loss of $348.9 million for the six months.
• The Self Care segment experienced a 7.7% decrease in net sales for the six months, while the Infant Formula segment saw a 23.1% increase in net sales for the three months ended June 27, 2026.
• The company is undergoing restructuring initiatives, including the Operational Enhancement Program, expected to yield $80 million to $100 million in gross pre-tax annual run rate cost savings.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant operating losses, substantial goodwill impairments, and ongoing legal proceedings, despite some positive developments like divestiture gains and improved infant formula segment performance.

Positives

• Completed the sale of the Dermacosmetics Business for $362.9 million, resulting in a pre-tax gain of $129.5 million.
• Infant Formula segment net sales increased by 23.1% for the three months ended June 27, 2026, and 12.3% for the six months ended June 27, 2026.
• The company is implementing cost-saving measures through the Operational Enhancement Program, targeting $80 million to $100 million in gross pre-tax annual run rate cost savings.
• Favorable foreign currency translation provided a $33.8 million increase in net sales for the six months ended June 27, 2026.
• The company reported compliance with all covenants under its debt agreements as of June 27, 2026.
• The company received a net receivable of approximately $31 million related to potential refunds of previously paid tariffs.

Negatives

• Reported a net loss of $324.1 million for the six months ended June 27, 2026, a significant increase from the $14.8 million net loss in the prior year period.
• Recorded a substantial goodwill impairment charge of $331.8 million during the six months ended June 27, 2026.
• Net sales decreased by 5.2% to $1,992.0 million for the six months ended June 27, 2026.
• Operating income for the six months was a loss of $348.9 million, a significant deterioration from an operating income of $92.3 million in the prior year.
• The Self Care segment experienced a 7.7% decrease in net sales for the six months.
• The Specialty Care segment's operating income decreased by 27.9% for the three months ended June 27, 2026.
• The company faces ongoing legal proceedings, including price-fixing lawsuits and securities litigation, with a loss accrual for litigation contingencies of $91.9 million as of June 27, 2026.

Risks

• Continued macroeconomic uncertainty, including inflation, interest rates, and volatile foreign currency exchange rates, could adversely affect sales and operating margins.
• Supply chain disruptions and inflationary pressures stemming from geopolitical tensions, such as the conflicts in Ukraine and the Middle East, pose ongoing risks.
• The infant formula business faces heightened competition, regulatory scrutiny, and challenges in recovering market share.
• Ongoing legal proceedings, including price-fixing lawsuits and securities litigation, could result in material adverse effects on financial condition, results of operations, or cash flows.
• Potential for future goodwill impairments if reporting unit performance deteriorates or macroeconomic factors increase discount rates.
• The company's credit ratings could be impacted by changes in operating performance, the economic environment, or business strategy, affecting future borrowing costs and access to capital.

Future Outlook

The company is focused on stabilizing, streamlining, and strengthening its business through initiatives like the Operational Enhancement Program, which aims to deliver $80 million to $100 million in gross pre-tax annual run rate cost savings. Management believes its operations and borrowing resources are sufficient for short-term and long-term capital requirements, but acknowledges potential impacts from macroeconomic uncertainties and legal matters.

Management Comments

• Perrigo is a leading pure-play self-care company with more than a century of providing high-quality health and wellness solutions to meet the evolving needs of consumers.
• Our strategic goal is to create sustainable and value accretive growth by delivering consumer preferred brands and innovation, driving category growth with our customers, powering our business with our world-class, quality assured supply chain, and evolving our global organization to one cohesive operating model.
• The Company's plan to drive increased cash flow and total shareholder return is anchored in its Three-S plan: Stabilizing, Streamlining, and Strengthening our business.
• We expect the Operational Enhancement Program to enhance organizational effectiveness by evolving our structure to improve agility, accelerate decision-making and better leverage technology.
• Management believes that our operations and borrowing resources are sufficient to provide for our short-term and long-term capital requirements.

Industry Context

StockSavvy.ai notes that Perrigo's performance reflects broader trends in the consumer healthcare sector, including increased competition, supply chain pressures, and a focus on strategic portfolio management through divestitures and restructuring. The company's emphasis on self-care aligns with growing consumer demand for accessible health solutions.

Comparison to Industry Standards

• The company's gross profit margin of 30.7% for the three months ended June 27, 2026, is below the typical margins seen in the consumer staples sector, which can range from 35% to 50% for established players.
• The significant goodwill impairment charges ($331.8 million) suggest potential overpayment for past acquisitions or a decline in the value of acquired businesses, a risk that has affected other companies in the pharmaceutical and consumer goods sectors during periods of economic uncertainty.
• Perrigo's net sales decline of 5.2% for the six-month period is concerning when compared to competitors like Procter & Gamble or Johnson & Johnson, which have generally maintained or grown sales in their consumer health segments, albeit with different product portfolios.
• The company's focus on restructuring and cost-saving initiatives, such as the Operational Enhancement Program, is a common strategy employed by companies facing margin pressure or seeking to improve efficiency, similar to actions taken by other large consumer goods manufacturers.

Management Changes

Legal Proceedings

• Price-Fixing Lawsuits Related to the Company's Former Rx Business: Numerous lawsuits alleging anticompetitive conduct in the sale of generic drugs. A liability for probable loss is reported.
• Securities Litigation: A purported securities class action complaint filed on November 17, 2025, related to statements made about the infant formula business.
• Talcum Powder Lawsuits: Allegations that talcum powder products cause mesothelioma and lung cancer due to asbestos contamination. Approximately 220 pending lawsuits.
• Ranitidine Lawsuits: Claims related to potential N-nitrosodimethylamine (NDMA) contamination. Most claims have been dismissed, with immaterial settlements expected to be funded by insurance.
• Acetaminophen MDL: Allegations that prenatal exposure to acetaminophen is associated with autism spectrum disorder and ADHD. Appeals are proceeding in the Second Circuit.
• Oral Phenylephrine Marketing and Sales Practices Litigation: Lawsuits asserting economic injury claims due to the efficacy of orally administered phenylephrine. Dismissal of most state law claims affirmed on appeal.
• PLD & Conry Litigation: Lawsuits alleging anticompetitive conduct related to infant formula manufacturing and acquisition. An agreement in principle to settle claims against Perrigo has been reached.

Stakeholder Impact

• Shareholders: Negative impact due to net losses, goodwill impairments, and a decline in operating income, although the divestiture gain provided some offset. Ongoing legal proceedings pose potential future financial risks.
• Employees: Potential impact from workforce reductions (approximately 7%) as part of the Operational Enhancement Program.
• Customers: Continued provision of self-care products, with potential benefits from innovation and value offerings. However, some customers are involved in indemnity claims related to legal proceedings.
• Creditors: The company remains in compliance with debt covenants, indicating stability for creditors in the short term, but future borrowing costs could be affected by credit rating changes.

Next Steps

• Continue to execute the Operational Enhancement Program to achieve targeted cost savings.
• Complete the strategic review of the infant formula business.
• Continue to monitor and manage macroeconomic uncertainties and geopolitical risks.
• Work collaboratively with the FDA to address matters raised in the February 2026 Form 483 inspection of the Perrigo Wisconsin infant formula facility.
• Defend vigorously against ongoing legal proceedings.

Key Dates

Recommendation

While the divestiture of the Dermacosmetics Business and the strategic review of the infant formula business indicate a focus on portfolio optimization, the significant operating losses, substantial goodwill impairments, and ongoing legal challenges present considerable headwinds. The company's restructuring efforts and cost-saving initiatives are positive steps, but their full impact remains to be seen. The current financial performance and risk profile warrant a 'hold' recommendation, pending clearer signs of sustained operational improvement and resolution of legal matters.

Keywords

Perrigo, 10-Q, Self Care, Specialty Care, Infant Formula, Goodwill Impairment, Divestiture, Restructuring